Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026 
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling 
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand 
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties 
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
Seatrium Reaches $475 Million Settlement With Maersk Over Offshore Wind Vessel Project 
 Clearance to Offer a Non-Prescription Version of BlueStar® Digital Therapeutic for Type 2 Diabetes - EconoTimes)
COLUMBIA, Md., Jan. 19, 2017 -- Digital health leader WellDoc announced today that the U.S. Food and Drug Administration (FDA) has granted the Company 510(k) class II clearance for a non-prescription version of the BlueStar® digital therapeutic. This BlueStar® option will allow WellDoc more flexibility in offering the product through additional channels to adults living with type 2 diabetes.
“This FDA clearance is a significant milestone for WellDoc,” said Kevin McRaith, WellDoc President & CEO. “We can now integrate BlueStar® more seamlessly into the healthcare ecosystem as we commercialize the product and significantly scale it by working with our existing partners as well as others with which we are actively engaged.”
Based on this clearance, WellDoc will offer BlueStar® and BlueStar® Rx. The non-prescription version will have all the first-in-class features of BlueStar® Rx apart from an insulin calculator. BlueStar® Rx will continue to include an insulin calculator for users to access and support their mealtime insulin dosing calculations. Additionally, this clearance allows BlueStar’s easy integration into health plan systems.
“We feel the optionality of multiple versions now greatly enhances the business potential for BlueStar® by allowing more options for payers to adopt it and expand access across their networks,” said WellDoc’s Head of Market Access Nick Harsh. “This clearance provides payers broader opportunities to use a proven tool that has demonstrated significant clinical outcomes to help better serve their adult members living with type 2 diabetes.”
This news comes on the heels of two other significant recent announcements for BlueStar®: the FDA’s clearance of the wireless integration of LifeScan’s OneTouch Verio Flex® blood glucose monitoring system with BlueStar®, and plans to incorporate the American Association of Diabetes Educators’ (AADE) curriculum in the BlueStar® digital therapeutic platform. The AADE/WellDoc partnership marks the first time AADE has collaborated with an organization to provide its curriculum in a consumer-friendly digital format.
About WellDoc®
WellDoc is a digital health technology company that develops mobile solutions to drive behavioral and clinical change in chronic disease. WellDoc’s goal is to improve patient self-management and help physicians overcome gaps in the delivery system to improve clinical outcomes and decrease cost. WellDoc has commercialized BlueStar®, a digital therapeutic, for adults with type 2 diabetes. This therapeutic is designed to fill the support gap between patients and providers during the 8700 hours that individuals live their lives outside the healthcare system each year. WellDoc has a proven track record of contributing published, peer-reviewed clinical evidence of a 1.7 to 2.0 point AIC reduction and has presented real-world patient engagement and clinical outcomes at important scientific meetings. BlueStar® is recognized by the ADA on its website as the first and only in the new class of diabetes treatment known as Mobile Prescription Therapy. In a recently published Forbes blog, WellDoc was named among one of five healthcare tech companies to watch in 2016. For more information, visit www.WellDoc.com and www.BlueStarDiabetes.com.
Media Contact: Juliette Bogus PressComm PR Tel: +410.980.5687 Email: [email protected]
